article thumbnail

Eurofins Genomics and Olink partner to advance proteomics research

Drug Discovery World

Eurofins Genomics has adopted Olink technology to advance proteomics research and accelerate its precision medicine programmes. The collaboration is designed to bolster the company’s offerings in the fields of research, population health, and regulated clinical trials. To read this content in full, you need to login.

Genome 59
article thumbnail

Junk DNA: How the dark genome is changing RNA therapies

Drug Discovery World

Decoding ‘junk DNA’ The Human Genome Project and subsequent studies discovered that most of our DNA (approximately 98%) does not actually code for proteins, with humans having approximately 20,000 tox 25,000 protein-coding genes.

RNA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

RNA editing protein ADAR1 protects telomeres and supports proliferation in cancer cells

Scienmag

Credit: The Wistar Institute PHILADELPHIA — (March 12, 2021) — Scientists at The Wistar Institute identified a new function of ADAR1, a protein responsible for RNA editing, discovering that the ADAR1p110 isoform regulates genome […].

RNA 92
article thumbnail

The architect of genome folding

Scienmag

Epigenetic regulator HPI1a drives de novo genome reorganization in early Drosophila embryos Credit: MPI of Immunobiology and Epigenetics, F. Instead, it is folded in a very organized way by the help of different proteins to establish a unique spatial organization of the genetic information. This […].

Genome 56
article thumbnail

The future of genomic medicine: can it fulfil its promises?

pharmaphorum

Here he gives us a deeper look at how genomic medicine is evolving and the barriers that are preventing it from reaching its full potential. I saw this, in particular, with the finishing of the human genome,” says Charlie. “At In reality, finishing the human genome was the first step of what is a long journey.”.

Genome 108
article thumbnail

3D genomics and targeted cancer therapies

Drug Discovery World

Anthony Schmitt , PhD, Senior Vice President, Science at Arima Genomics, discusses the applications of 3D genomics in cancer research. But what about the patients whose genomic tests do not identify a cancer driver matched to an existing targeted therapy? with regards to detecting cancer driver mutations.

Genome 52
article thumbnail

#news #biotech A ‘genomic rosetta stone’ for discovering the rules of gene regulation

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: A ‘genomic rosetta stone’ for discovering the rules of gene regulation.As

Genome 40